1[1]Minsky BD. Adjuvant therapy for rectal cancer:results and controversies[J]. Oncology, 1998,12(8): 1129-1139.
2[2]Bosset JF,Magnin V, Maingon P, et al. Preoperative radiochemotherapy in rectal cancer: long term results of a phase Ⅱ trial[J]. Int J Radiat Oncol Biol Phys,2000,46(2):323-327.
3[3]Foo KF, Micheal M, Zalcberg J. Adjuvant theraphy for rectal cancer[J]. Semin Colon Rectum Surg, 2002,13(4):259-268.
4[4]Sawada N, Ishikawa T, Sakiguchi F, et al. X-ray irradiati on induces thymidine phosphorylase and enhances the efficacy of capecitabine(Xeloda) in human cancer xenografts [J]. Clin Cancer Res, 1999,5:2948-2953.
5Heald RJ, Husband EM, Ryall RDH.The mesotrtum in rectal cancer surgery - the clue to pelvic recurrence? Br Surg, 1982,69:613-616.
6Heald RJ, Ryall RDH. Recurrence survival after total mesorectal excision for rectalcancer. Lancet, 1986,1: 1479-1482.
7Hojo K, Sawada T, Moriya Y. An analysis of survival and voiding, sexual functionafter wide iliopelvic lymphadenectomy in patients with carcinoma of the rectum comparedwith conventional lymphadenectomy. Dis Colon Retum, 1989,32: 128-133.
8Sugihara K, Moriya Y, Akasu T, et al. Pelvic autonomic nerve preservation forpatients with rectal carcinoma. Oncologic and functional outcome. Cancer, 1996,78:1871-80.
9Moriya Y, Augihara K, Akasu T, et al. Importance of extended lymphadenectomy withlateral node dissection for advanced lower rectal cancer. World J Surg, 1997,21: 728-732.
10Heald RJ, Chir M, Karanjia NS. Results of radical surgery. World J Surg, 1992, 16:848-857.
